Payment overview · 2025
General Payments
$7,541.80
294 reported records · 43 companies
Healthcare provider profile · identity verified
Lawrence Mark Eilender, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SOUTHFIELD, MI · NPI 1366445173
Verified facts
What the public records show
CMS Open Payments records show Lawrence Mark Eilender, MD received $7,541.80 in general payments during 2025 across 294 reported records.
LivaNova USA, Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 60 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bafiertam, Ingrezza, Nuplazid, Qulipta, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vumerity by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Privigen by this doctor in 2024.
Cycle Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Bafiertam as an associated drug or biological on 1343 records involving 850 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bafiertam by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $1,621.25 | 21.5% | 10 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $511.68 | 6.8% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $445.79 | 5.9% | 36 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $433.04 | 5.7% | 14 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $398.96 | 5.3% | 22 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $382.33 | 5.1% | 17 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $288.61 | 3.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.57 | 3.4% | 16 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $227.01 | 3.0% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $217.56 | 2.9% | 9 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.20 | 2.8% | 12 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $206.13 | 2.7% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $200.27 | 2.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.59 | 2.5% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $183.72 | 2.4% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $181.03 | 2.4% | 7 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $156.18 | 2.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.04 | 1.7% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $129.23 | 1.7% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $111.59 | 1.5% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $100.47 | 1.3% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.22 | 1.2% | 5 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $85.64 | 1.1% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $80.01 | 1.1% | 5 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$78.06 | 1.0% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.76 | 0.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.66 | 0.8% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $57.50 | 0.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $53.33 | 0.7% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $53.15 | 0.7% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $38.11 | 0.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $36.62 | 0.5% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.81 | 0.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $31.74 | 0.4% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$29.28 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.10 | 0.3% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.04 | 0.3% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $23.55 | 0.3% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $22.82 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22.19 | 0.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.90 | 0.2% | 1 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $16.41 | 0.2% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,290.28 | 289 |
| Travel and Lodging | $1,101.52 | 4 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VNS Therapy Normalized: vns therapy |
Device | LivaNova USA, Inc. | $1,562.03 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $445.79 | 36 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $382.33 | 17 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $381.75 | 12 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $288.61 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $271.69 | 15 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $217.56 | 9 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $206.13 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $200.27 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $194.77 | 11 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $186.59 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $173.29 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $160.70 | 10 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $157.74 | 9 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $152.70 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $152.52 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $152.24 | 7 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $128.25 | 8 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $128.02 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $114.34 | 7 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $113.33 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $111.27 | 5 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $100.47 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $90.22 | 5 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $83.72 | 6 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $81.95 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $80.01 | 5 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $78.06 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $70.76 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $62.25 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $59.22 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $53.16 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $53.15 | 3 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $51.29 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $46.23 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $42.85 | 2 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., Octapharma USA, Inc. | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $38.11 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $34.65 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $31.81 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $31.74 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $31.02 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $25.04 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Ormalvi Normalized: ormalvi |
Drug | Cycle Pharmaceuticals Inc | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Bafiertam bafiertam |
2025 | Bafiertam | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Cycle Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Bafiertam open payments reported associated product |
CMS Open Payments — General Payments 1343 supporting records · 850 recipient NPIs · example record 1248898758 |
Bafiertam · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 782 | 235 |
| Memantine Hcl | Memantine Hcl | 524 | 118 |
| Duloxetine Hcl | Duloxetine Hcl | 366 | 103 |
| Baclofen | Baclofen | 349 | 105 |
| Donepezil Hcl | Donepezil Hcl | 264 | 70 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 256 | 71 |
| Topiramate | Topiramate | 205 | 61 |
| Levetiracetam | Levetiracetam | 182 | 41 |
| Prednisone | Prednisone | 145 | 88 |
| Lamotrigine | Lamotrigine | 140 | 33 |
| Clonazepam | Clonazepam | 129 | 31 |
| Trazodone Hcl | Trazodone Hcl | 128 | 38 |
| Primidone | Primidone | 124 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 119 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 106 | 33 |
| Sumatriptan Succinate | Sumatriptan Succinate | 102 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 19 |
| Tramadol Hcl | Tramadol Hcl | 87 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 25 |
| Alprazolam | Alprazolam | 82 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 20 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 76 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 76 | 20 |
| Oxcarbazepine | Oxcarbazepine | 65 | 17 |
| Modafinil | Modafinil | 64 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 18 |
| Diazepam | Diazepam | 62 | 25 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 61 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 60 | 14 |
| Emgality Pen | Galcanezumab-Gnlm | 57 | 11 |
| Carbamazepine | Carbamazepine | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 54 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 54 | 12 |
| Pregabalin | Pregabalin | 54 | 15 |
| Sertraline Hcl | Sertraline Hcl | 54 | 15 |
| Carbamazepine Er | Carbamazepine | 52 | 13 |
| Methocarbamol | Methocarbamol | 50 | 19 |
| Dalfampridine Er | Dalfampridine | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 14 |
| Ibuprofen | Ibuprofen | 47 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 47 | 14 |
| Omeprazole | Omeprazole | 47 | suppressed |
| Amantadine | Amantadine Hcl | 44 | 19 |
| Teriflunomide | Teriflunomide | 44 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 41 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 37 | suppressed |
| Rivastigmine | Rivastigmine | 37 | suppressed |
| Kesimpta Pen | Ofatumumab | 36 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | 14 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | 11 |
| Qulipta | Atogepant | 30 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 29 | suppressed |
| Austedo | Deutetrabenazine | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 27 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Fingolimod | Fingolimod Hcl | 25 | suppressed |
| Keppra Xr | Levetiracetam | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Vumerity | Diroximel Fumarate | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Copaxone | Glatiramer Acetate | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Zolmitriptan | Zolmitriptan | 16 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Ampyra | Dalfampridine | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Bafiertam | Monomethyl Fumarate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Trileptal | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,541.80 · 294 records | LivaNova USA, Inc. | AJOVY, AMVUTTRA, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, EPIDIOLEX, FIRDAPSE, FYCOMPA, Fintepla, HYQVIA, Hizentra, INFINITY, INGREZZA, KESIMPTA, KEVEYIS, KISUNLA, Leqembi, Mavenclad, Motpoly XR, NEUROSTAR TMS THERAPY SYSTEM, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus, Ocrevus Zunovo, Ormalvi, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Radicava, Rystiggo, SKYCLARYS, Senza, Sunosi, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VNS Therapy, VRAYLAR, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, ZAVZPRET, ZEPOSIA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bafiertam play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error